NCT00993863View on ClinicalTrials.gov

Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction

PHASE2CompletedINTERVENTIONAL

Enrollment

201

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

September 30, 2007

Conditions

Acute Pain

Interventions

DRUG

Placebo

single dose

DRUG

ADL5859 30 mg

single dose

DRUG

ADL5859 100 mg

single dose

DRUG

ADL5859 200 mg

single dose

DRUG

ibuprofen 400 mg

single dose

Trial Locations (1)

78705

SCIREX Research Center, Austin

All Listed Sponsors

lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00993863 - Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction | Biotech Hunter | Biotech Hunter